AcelRx Pharmaceuticals, a California-based company specializing in pharmaceuticals, is dedicated to developing and commercializing therapies that target acute pain. Its primary focus is on DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet designed to treat moderate-to-severe acute pain. The company also has several other product candidates in development, including ZALVISO, a patient-controlled analgesia system, and ARX-02 and ARX-03, both of which are undergoing Phase 2 clinical trials. AcelRx's comprehensive product lineup also includes Niyad and LTX-608, which are anticoagulant and antiviral treatments, respectively. Additionally, the company is exploring the development of Fedsyra and phenylephrine, pre-filled syringes containing ephedrine and phenylephrine, respectively. AcelRx Pharmaceuticals was first established in 2005 as SuRx before changing its name in 2006. The company's headquarters are located in Hayward, California.
AcelRx Pharmaceuticals's ticker is ACRX
The company's shares trade on the NASDAQ stock exchange
They are based in Redwood City, California
There are 51-200 employees working at AcelRx Pharmaceuticals
It is acelrx.com/company/founders-story
AcelRx Pharmaceuticals is in the Healthcare sector
AcelRx Pharmaceuticals is in the Medical Appliances & Equipment industry
The following five companies are AcelRx Pharmaceuticals's industry peers: